Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARKG ARK Genomic Revolution ETF	$24.79 +5.0%	$24.74	$17.51 ▼ $31.16	$1.38B	1.62	2.73 million shs	4.90 million shs
ARKK ARK Innovation ETF	$74.53 +0.2%	$74.21	$38.57 ▼ $79.19	$7.21B	1.64	11.57 million shs	4.05 million shs
BEAM Beam Therapeutics	$18.37 +12.7%	$18.69	$13.52 ▼ $35.25	$1.86B	2.14	2.11 million shs	6.40 million shs
GOOGL Alphabet	$228.35 +8.0%	$192.29	$140.53 ▼ $231.05	$2.76T	1.01	36.50 million shs	76.60 million shs
LLY Eli Lilly and Company	$734.05 -0.2%	$747.03	$623.78 ▼ $954.00	$694.68B	0.47	4.15 million shs	1.15 million shs
VERV Verve Therapeutics	$11.13	$11.13	$2.86 ▼ $11.40	$992.13M	2.23	3.94 million shs	N/A
VRTX Vertex Pharmaceuticals	$393.80 -1.8%	$431.31	$362.50 ▼ $519.88	$100.91B	0.44	1.64 million shs	623,618 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARKG ARK Genomic Revolution ETF	+0.29%	-0.40%	+5.33%	+10.08%	-5.97%
ARKK ARK Innovation ETF	-0.73%	-2.44%	+4.57%	+28.34%	+66.02%
BEAM Beam Therapeutics	-0.31%	-1.98%	-13.38%	-4.90%	-38.87%
GOOGL Alphabet	-0.73%	+2.03%	+11.75%	+25.77%	+29.36%
LLY Eli Lilly and Company	+0.29%	-0.05%	-3.53%	-4.20%	-23.48%
VERV Verve Therapeutics	0.00%	0.00%	0.00%	+110.40%	+66.12%
VRTX Vertex Pharmaceuticals	+2.55%	+3.57%	-13.23%	-10.06%	-19.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARKG ARK Genomic Revolution ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ARKK ARK Innovation ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	2.3667 of 5 stars	3.5	0.0	0.0	0.0	3.1	2.5	0.6
GOOGL Alphabet	3.7235 of 5 stars	2.4	3.0	1.7	0.0	3.4	2.5	2.5
LLY Eli Lilly and Company	5 of 5 stars	4.3	3.0	3.3	4.0	2.6	3.3	3.8
VERV Verve Therapeutics	2.1254 of 5 stars	4.2	0.0	0.0	0.0	0.0	2.5	0.0
VRTX Vertex Pharmaceuticals	4.9819 of 5 stars	4.3	5.0	0.0	3.3	3.6	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARKG ARK Genomic Revolution ETF	2.68	Moderate Buy	$24.79	N/A
ARKK ARK Innovation ETF	2.59	Moderate Buy	$74.68	0.21% Upside
BEAM Beam Therapeutics	3.07	Buy	$48.45	163.71% Upside
GOOGL Alphabet	2.86	Moderate Buy	$219.11	-4.05% Downside
LLY Eli Lilly and Company	2.67	Moderate Buy	$950.17	29.44% Upside
VERV Verve Therapeutics	2.33	Hold	$14.57	30.92% Upside
VRTX Vertex Pharmaceuticals	2.56	Moderate Buy	$497.10	26.23% Upside

Current Analyst Ratings Breakdown

Latest VERV, GOOGL, ARKG, ARKK, LLY, VRTX, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2025	GOOGL Alphabet	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
9/3/2025	GOOGL Alphabet	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
9/3/2025	GOOGL Alphabet	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$220.00 ➝ $260.00
9/3/2025	GOOGL Alphabet	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$235.00 ➝ $250.00
9/3/2025	GOOGL Alphabet	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$230.00 ➝ $265.00
9/3/2025	GOOGL Alphabet	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$225.00 ➝ $250.00
9/3/2025	GOOGL Alphabet	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$225.00 ➝ $245.00
9/3/2025	GOOGL Alphabet	Rosenblatt Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$191.00 ➝ $224.00
9/3/2025	GOOGL Alphabet	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$220.00 ➝ $260.00
9/2/2025	GOOGL Alphabet	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$235.00 ➝ $270.00
9/2/2025	VRTX Vertex Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform

(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARKG ARK Genomic Revolution ETF	N/A	N/A	N/A	N/A	N/A	N/A
ARKK ARK Innovation ETF	N/A	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	$63.52M	29.26	N/A	N/A	$10.35 per share	1.78
GOOGL Alphabet	$371.40B	7.44	$10.15 per share	22.49	$30.01 per share	7.61
LLY Eli Lilly and Company	$45.04B	15.42	$14.26 per share	51.47	$19.39 per share	37.86
VERV Verve Therapeutics	$32.33M	30.69	N/A	N/A	$5.83 per share	1.91
VRTX Vertex Pharmaceuticals	$11.02B	9.16	N/A	N/A	$66.99 per share	5.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARKG ARK Genomic Revolution ETF	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ARKK ARK Innovation ETF	N/A	N/A	50.14	∞	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	-$376.74M	-$4.50	N/A	N/A	N/A	-661.31%	-43.15%	-31.06%	11/4/2025 (Estimated)
GOOGL Alphabet	$100.12B	$9.39	24.32	22.32	1.43	31.12%	34.31%	24.88%	11/4/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$15.30	47.97	23.59	1.02	25.91%	92.72%	16.89%	10/29/2025 (Estimated)
VERV Verve Therapeutics	-$198.71M	-$2.11	N/A	N/A	N/A	-303.64%	-35.81%	-27.57%	N/A
VRTX Vertex Pharmaceuticals	-$535.60M	$13.99	28.13	22.49	N/A	31.86%	23.91%	17.14%	11/3/2025 (Estimated)

Latest VERV, GOOGL, ARKG, ARKK, LLY, VRTX, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	-$1.00	+$0.04	-$1.00	$13.29 million	$8.47 million
8/4/2025	Q2 2025	VRTX Vertex Pharmaceuticals	$4.24	$4.52	+$0.28	$3.99	$2.90 billion	$2.94 billion
7/23/2025	Q2 2025	GOOGL Alphabet	$2.15	$2.31	+$0.16	$5.12	$93.60 billion	$96.43 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARKG ARK Genomic Revolution ETF	N/A	N/A	N/A	N/A	N/A
ARKK ARK Innovation ETF	$0.36	0.48%	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
GOOGL Alphabet	$0.84	0.37%	N/A	8.95%	1 Years
LLY Eli Lilly and Company	$6.00	0.82%	N/A	39.22%	11 Years
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest VERV, GOOGL, ARKG, ARKK, LLY, VRTX, and BEAM Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/21/2025	GOOGL Alphabet	quarterly	$0.21	0.4%	9/8/2025	9/8/2025	9/15/2025
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARKG ARK Genomic Revolution ETF	N/A	N/A	N/A
ARKK ARK Innovation ETF	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	6.75	6.75
GOOGL Alphabet	0.07	1.90	1.90
LLY Eli Lilly and Company	1.86	1.28	1.00
VERV Verve Therapeutics	N/A	9.84	9.84
VRTX Vertex Pharmaceuticals	N/A	2.52	2.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARKG ARK Genomic Revolution ETF	N/A
ARKK ARK Innovation ETF	N/A
BEAM Beam Therapeutics	99.68%
GOOGL Alphabet	40.03%
LLY Eli Lilly and Company	82.53%
VERV Verve Therapeutics	97.11%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
ARKG ARK Genomic Revolution ETF	N/A
ARKK ARK Innovation ETF	N/A
BEAM Beam Therapeutics	3.50%
GOOGL Alphabet	11.64%
LLY Eli Lilly and Company	0.14%
VERV Verve Therapeutics	19.30%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARKG ARK Genomic Revolution ETF	N/A	44.70 million	N/A	Not Optionable
ARKK ARK Innovation ETF	N/A	96.80 million	N/A	Not Optionable
BEAM Beam Therapeutics	510	101.16 million	97.62 million	Optionable
GOOGL Alphabet	183,323	12.09 billion	10.70 billion	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.13 million	Optionable
VERV Verve Therapeutics	110	89.14 million	71.94 million	Optionable
VRTX Vertex Pharmaceuticals	6,100	256.39 million	255.88 million	Optionable

VERV, GOOGL, ARKG, ARKK, LLY, VRTX, and BEAM Headlines

Recent News About These Companies

Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report?

3 hours ago | zacks.com

Here’s Why Vertex Pharmaceuticals (VRTX) is on Loomis Sayles Growth Fund’s Detractors List

September 3 at 8:30 AM | insidermonkey.com

Vertex teams with Enlaza to expand gene therapy options

September 3 at 8:18 AM | thepharmaletter.comT

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by PDT Partners LLC

September 3 at 8:13 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX Stock Position Reduced by GW Henssler & Associates Ltd.

September 3 at 8:03 AM | marketbeat.com

1248 Management LLC Cuts Holdings in Vertex Pharmaceuticals Incorporated $VRTX

September 3 at 7:40 AM | marketbeat.com

Paloma Partners Management Co Invests $407,000 in Vertex Pharmaceuticals Incorporated $VRTX

September 3 at 7:31 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Royal Bank of Canada

September 3 at 6:38 AM | marketbeat.com

Vertex Pharmaceuticals initiated with a Market Perform at Raymond James

September 2 at 9:13 PM | msn.com

Vertex Pharmaceuticals Incorporated (VRTX) Slid on Softer Revenue and Earnings

September 2 at 9:51 AM | insidermonkey.com

Flputnam Investment Management Co. Has $17.69 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX

September 2 at 9:49 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (VRTX) Slid on Softer Revenue and Earnings

September 2 at 9:30 AM | finance.yahoo.com

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Armistice Capital LLC

September 2 at 8:12 AM | marketbeat.com

2,000 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Retirement Planning Co of New England Inc.

September 2 at 8:12 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Cyrus J. Lawrence LLC

September 2 at 8:11 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Jump Financial LLC

September 2 at 4:24 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

September 1 at 4:04 PM | finance.yahoo.com

Vident Advisory LLC Sells 3,756 Shares of Vertex Pharmaceuticals Incorporated $VRTX

September 1 at 5:52 AM | marketbeat.com

Canada Pension Plan Investment Board Decreases Stock Position in Vertex Pharmaceuticals Incorporated $VRTX

September 1 at 5:36 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by The Manufacturers Life Insurance Company

August 31 at 7:24 AM | marketbeat.com

Te Ahumairangi Investment Management Ltd Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

August 31 at 6:51 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VERV, GOOGL, ARKG, ARKK, LLY, VRTX, and BEAM Company Descriptions

ARK Genomic Revolution ETF BATS:ARKG

$24.79 +1.18 (+5.01%)

As of 02:49 PM Eastern

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.

ARK Innovation ETF NYSEARCA:ARKK

$74.53 +0.12 (+0.16%)

As of 02:49 PM Eastern

The ARK Innovation ETF (ARKK) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that seeks long-term capital growth from companies globally involved with, or that benefit from, disruptive innovation. ARKK was launched on Oct 31, 2014 and is managed by ARK.

Beam Therapeutics NASDAQ:BEAM

$18.37 +2.06 (+12.65%)

As of 02:49 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Alphabet NASDAQ:GOOGL

$228.35 +17.00 (+8.04%)

As of 02:49 PM Eastern

Alphabet Inc. offers various products and platforms in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Canada, and Latin America. It operates through Google Services, Google Cloud, and Other Bets segments. The Google Services segment provides products and services, including ads, Android, Chrome, devices, Gmail, Google Drive, Google Maps, Google Photos, Google Play, Search, and YouTube. It is also involved in the sale of apps and in-app purchases and digital content in the Google Play and YouTube; and devices, as well as in the provision of YouTube consumer subscription services. The Google Cloud segment offers infrastructure, cybersecurity, databases, analytics, AI, and other services; Google Workspace that include cloud-based communication and collaboration tools for enterprises, such as Gmail, Docs, Drive, Calendar, and Meet; and other services for enterprise customers. The Other Bets segment sells healthcare-related and internet services. The company was incorporated in 1998 and is headquartered in Mountain View, California.

Eli Lilly and Company NYSE:LLY

$734.05 -1.14 (-0.16%)

As of 02:49 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Verve Therapeutics NASDAQ:VERV

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Vertex Pharmaceuticals NASDAQ:VRTX

$393.80 -7.20 (-1.80%)

As of 02:49 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VERV, GOOGL, ARKG, ARKK, LLY, VRTX, and BEAM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VERV, GOOGL, ARKG, ARKK, LLY, VRTX, and BEAM Earnings

Compare Dividends

Latest VERV, GOOGL, ARKG, ARKK, LLY, VRTX, and BEAM Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VERV, GOOGL, ARKG, ARKK, LLY, VRTX, and BEAM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VERV, GOOGL, ARKG, ARKK, LLY, VRTX, and BEAM Company Descriptions

ARK Genomic Revolution ETF BATS:ARKG

ARK Innovation ETF NYSEARCA:ARKK

Beam Therapeutics NASDAQ:BEAM

Alphabet NASDAQ:GOOGL

Eli Lilly and Company NYSE:LLY

Verve Therapeutics NASDAQ:VERV

Vertex Pharmaceuticals NASDAQ:VRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools